Which big biopharma companies put R&D as their top priority?
We love charts at Endpoints. They’re a great way to offer a snapshot of the data that highlight a dramatic comparison for readers. So we were delighted when one of our readers came up with two new charts from last week’s special report on the top 15 R&D budgets in biopharma.
Aris Angelis, research officer and PhD candidate at the London School of Economics, first went to work comparing how the companies did at research spending as a comparison to the percentage of revenue spent on research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.